This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barton, B. E. Articles by Barton, A. Search for Related Content PubMed PubMed Citation Articles by Barton, B. E. Articles by Barton, A.

¹ Division of Urology, Department of Surgery, ² Orthopedics Research Laboratory, and ³ Department of Microbiology and Molecular Genetics, University of Medicine and Dentistry-New Jersey Medical School, Newark, New Jersey

Requests for reprints: Beverly E. Barton, Division of Urology, Department of Surgery, University of Medicine and Dentistry-New Jersey Medical School, MSB G519, 185 South Orange Avenue, Newark, NJ 07103. Phone: 973-972-0662; Fax: 973-972-6803. E-mail: bartonbe{at}umdnj.edu

Signal transducers and activators of transcription (STAT) were originally discovered as components of cytokine signal transduction pathways. Persistent activation of one of these transcription factors, STAT3, is a feature of many malignancies, including hormone-resistant prostate cancer. In this regard, malignant cells expressing persistently activated STAT3 become dependent on it for survival, thus rendering STAT3 a potential molecular target for therapy of hormone-resistant prostate cancer. Previously, we reported that antisense oligonucleotides specific for STAT3 were better at inducing apoptosis than inhibitors of JAK1 or JAK2, the upstream activating kinases of STAT3. Here, we report that novel single-stranded oligonucleotides, which putatively block STAT3-DNA binding, were better at inducing hormone-resistant prostate cancer apoptosis than antisense STAT3 oligonucleotides. We observed that the novel STAT3-inhibiting oligonucleotides induced apoptosis by a mitochondrial-dependent pathway involving the activation of caspase-3. Prostate cell lines not expressing persistently activated STAT3 did not become apoptotic after treatment with these same oligonucleotides. Scrambled-sequence control oligonucleotides had none of the effects of the active sequence oligonucleotides on any variable measured. Furthermore, the novel STAT3-inhibiting oligonucleotides, but not scrambled-sequence control oligonucleotide, significantly reduced the volume of s.c. DU145 tumors in vivo. Histologic examination of the tumors revealed no infiltrate of mononuclear or granulocytic cells, which would be indicative of evocation of a nonspecific immune response by the oligonucleotides. We conclude that single-stranded oligonucleotides based on the binding sequences of STAT3 are an additional strategy to design inhibitors for this molecular target and that these inhibitors should be useful as experimental therapeutics for hormone-resistant prostate cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 1/12/04; revised 6/27/04; accepted 7/22/04.

This article has been cited by other articles:

				H. D. Lewis, A. Winter, T. F. Murphy, S. Tripathi, V. N. Pandey, and B. E. Barton STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends Mol. Cancer Ther., June 1, 2008; 7(6): 1543 - 1550. [Abstract] [Full Text] [PDF]

				D. A Frank Targeting Transcription Factors for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 335 - 341. [Abstract] [Full Text] [PDF]

				J. W. Darnowski, F. A. Goulette, Y.-j. Guan, D. Chatterjee, Z.-F. Yang, L. P. Cousens, and Y. E. Chin Stat3 Cleavage by Caspases: IMPACT ON FULL-LENGTH Stat3 EXPRESSION, FRAGMENT FORMATION, AND TRANSCRIPTIONAL ACTIVITY J. Biol. Chem., June 30, 2006; 281(26): 17707 - 17717. [Abstract] [Full Text] [PDF]

				Article on anti-STAT3 and prostate cancer Mol. Cancer Ther., December 1, 2004; 3(12): 1701 - 1701. [Full Text] [PDF]